I want you to try something.
Pull out your smartphone. Look at it for a moment.
This device can guide you through traffic in real-time, recognize your face in milliseconds, and translate dozens of languages instantly.
Now consider this absurdity: When you get strep throat, your doctor still does exactly what doctors did in the 1950s – sticks a wooden paddle in your mouth, peers down your throat with a flashlight, and makes their best guess.
That guess, by the way, is wrong 70% of the time.
This is why doctors write six antibiotic prescriptions for every ten sore throats they see, even though only two or three actually need antibiotics. It’s also why antibiotic resistance has become one of the World Health Organization’s top five global health threats.
But that’s about to change.
The Dental Pioneer Who Saw It Coming
Peter Whitehead isn’t your typical medical innovator. He’s the kind of entrepreneur who solves obvious problems that everyone else somehow misses.
His last invention – a dental imaging device called the VELscope – has been used in over 50 million oral examinations by more than 10,000 dental practitioners worldwide.
Now he’s doing it again. And this time, the market is exponentially larger.
Whitehead and his team have spent eight years building something remarkable: an artificial intelligence system that can identify strep throat from a smartphone photo in seconds – with over 96% accuracy.
Think about what that means…
No more unnecessary doctor visits. No more guesswork. No more needless antibiotics.
Just pull out your phone, take a photo, and get an answer.
The Three Doors to Billions
Here’s where it gets interesting. Most medical device companies have one path to market – the long, expensive FDA approval process.
But Whitehead’s company has three simultaneous routes:
First, there’s the direct-to-consumer wellness market. No FDA approval needed. Just launch the app and let people screen themselves before deciding if they need to see a doctor.
Second, they’ve partnered with a global healthcare platform that reaches 120,000 practitioners in emerging markets. These are places where access to quality healthcare is limited, but smartphones are everywhere.
Third, they’re pursuing FDA approval, with clinical trials already designed in partnership with Carelon (part of Elevance Health).
Any one of these paths could build a billion-dollar company.
They’re pursuing all three simultaneously.
Why This Matters Now
The former Chief Strategy Officer of Bristol Myers Squibb just joined the board. Johnson & Johnson, Medtronic, and other healthcare giants are already involved. The company has secured patents across multiple jurisdictions.
Here’s what fascinates us most…
While tech giants pour billions into counting steps and measuring sleep, this tiny company wants to turn every smartphone on earth into a medical testing device.
And strep throat is just the beginning.
The Hidden Urgency
600 million people get strep throat every year.
The world needs $100 billion in new solutions just to keep pace with antibiotic resistance.
And right now, a small company most people have never heard of is sitting on technology that could help solve both problems.
- Big Tech will eventually realize that smartphones can be used for real medical testing, not just wellness tracking.
When that happens, who do you think they’ll be looking to acquire?
On Monday we’ll reveal the name and ticker of this company.
Regards,
The Katusa Research Special Situations Team
IMPORTANT DISCLAIMER & DISCLOSURES
Investing in stocks is HIGH RISK. You could lose all of your investment.
Katusa Research, as a publisher, is not a broker, investment advisor, or financial advisor in any jurisdiction.
Please do not rely on the information presented by Katusa Research as personal investment advice.
If you need personal investment advice, kindly reach out to a qualified and registered broker, investment advisor, or financial advisor.
The communications from Katusa Research should not form the basis of your investment decisions. Examples we provide regarding share price increases related to specific companies are based on randomly selected time periods and should not be taken as an indicator or predictor of future stock prices for those companies.
LightAI Inc. is a paid sponsor of this report.
The information in this newsletter does not constitute an offer to sell or a solicitation of an offer to buy any securities of a corporation or entity, including U.S. Traded Securities or U.S. Quoted Securities, in the United States or to U.S. Persons. Securities may not be offered or sold in the United States except in compliance with the registration requirements of the Securities Act and applicable U.S. state securities laws or pursuant to an exemption therefrom.
Any public offering of securities in the United States may only be made by means of a prospectus containing detailed information about the corporation or entity and its management as well as financial statements. No securities regulatory authority in the United States has either approved or disapproved of the contents of any newsletter. Katusa Research nor any employee of Katusa Research is not registered with the United States Securities and Exchange Commission (the “SEC”): as a “broker-dealer” under the Exchange Act, as an “investment adviser” under the Investment Advisers Act of 1940, or in any other capacity. Katusa Research, its owners, directors, and employees are also not registered with any state securities commission or authority as a broker-dealer or investment advisor or in any other capacity.
HIGHLY BIASED: In our role, we aim to highlight specific companies for your further investigation; however, these are not stock recommendations, nor do they constitute an offer or sale of the referenced securities. Katusa Research partner company, New Era Publishing Inc. has received cash compensation in the amount of three hundred seventy-five thousand dollars from LightAI Corp. for a four-week marketing campaign. and is thus extremely biased. It is crucial that you conduct your own research prior to investing. This includes reading the companies’ SEDAR and SEC filings, press releases, and risk disclosures. The information contained herein regarding LightAI Inc. has been derived from its SEDAR+ and SEC filings, including scientific and technical information. Information regarding the projects underlying LightAI Inc.’s interests has been derived from the publicly available disclosure of the underlying operators and owners, including where referenced herein.
Katusa Research, and its directors, employees, and members of their households may own any shares of LightAi Inc (ALGO:CBOE). However, Katusa Research is extremely biased since this is a sponsored editorial.
HIGH RISK: The securities issued by the companies we feature should be seen as high risk; if you choose to invest, despite these warnings, you may lose your entire investment. You must be aware of the risks and be willing to accept them in order to invest in financial instruments, including stocks, options, and futures.
NOT PROFESSIONAL ADVICE: By reading this, you agree to all of the following: You understand this to be an expression of opinions and NOT professional advice. You are solely responsible for the use of any content and hold Katusa Research, and all partners, members, and affiliates harmless in any event or claim. While Katusa Research strives to provide accurate and reliable information sourced from believed-to-be trustworthy sources, we cannot guarantee the accuracy or reliability of the information. The information provided reflects conditions as they are at the moment of writing and not at any future date. Katusa Research is not obligated to update, correct, or revise the information post-publication.
FORWARD-LOOKING STATEMENTS: Certain information presented may contain or be considered forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in these statements. There can be no assurance that any such statements will prove to be accurate, and readers should not place undue reliance on such information. These statements are subject to known and unknown risks including those set forth in LightAI Inc.’s most recent annual information form and other public filings available at www.sedarplus.ca and www.sec.gov. Neither Katusa Research nor LightAI Inc. undertake any obligations to update the information presented or to ensure that such information remains current and accurate, except as required under applicable law.
